Competitor Analysis: Influenza Vaccines


May 1, 2011
123 Pages - SKU: LAM6329912
License type:
The present Competitive Intelligence Report about Influenza Vaccines provides a competitor evaluation in the field of marketed and novel prophylactic vaccines against seasonal and pandemic influenza viruses. Presentation of the vaccines is structured according to the manufacturing process: propagated in hens’ eggs or in cell culture, recombinant protein based vaccines and DNA based vaccines. Product description considers use of adjuvants and preservatives. Vaccines with nasal delivery are highlighted. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed vaccines and active projects in research and development for prophylaxis of seasonal and pandemic influenza disease. In addition, the report lists company-specific product portfolios and R&D pipelines of influenza vaccines on the market and in R&D. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.


Additional Information

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

More Pandemic Vaccines reports by La Merie Publishing

Competitor Analysis: Anthrax Vaccines and Therapeutics by La Merie Publishing
The present Competitive Intelligence Report about Anthrax Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies and small ...
See all reports like this >>